Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 4/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881668 | 0.90 | GNAO1 (0.40) | GNAI3GNAO1GNAI1MLNRCHRM2 | |
| SCHEMBL26504917 | 0.78 | HRH3 (0.38) | GNAO1 | |
| SCHEMBL21166176 | 0.78 | PDE4A (0.31) | — | |
| SCHEMBL21881661 | 0.77 | GNAO1 (0.44) | GNAI3GNAO1GNAI1MLNRCHRM2 | |
| SCHEMBL21214459 | 0.75 | CHRM3 (0.35) | GNAI3GNAO1GNAI1MLNRCHRM2 | |
| SCHEMBL19525523 | 0.75 | GNAI3 (0.35) | GNAI3GNAO1GNAI1 | |
| SCHEMBL18995658 | 0.75 | TP53 (0.34) | HRH1 | |
| SCHEMBL21579250 | 0.74 | CHRM3 (0.36) | GNAI3GNAO1GNAI1MLNRCHRM2 | |
| SCHEMBL21880925 | 0.72 | GNAO1 (0.37) | GNAI3GNAO1GNAI1CHRM1 | |
| SCHEMBL18995711 | 0.71 | GNAO1 (0.38) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | GNAI3 505/4885GNAO1 366/4885GNAI1 459/4885 |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | GNAI3 505/4885GNAO1 366/4885GNAI1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.